Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $165K | — | — | — | — | — | — |
| Operating income | -$26.7M | -$71.3M | -$170M | -$171M | -$200M | -$51.7M | -$46.2M |
| Operating margin | -16182.4% | — | — | — | — | — | — |
| Net income | -$23.8M | -$69.8M | -$172M | -$169M | -$190M | -$69.2M | -$43.4M |
| Net margin | -14447.9% | — | — | — | — | — | — |
| EPS (diluted) | -$18.54 | -$2.59 | -$2.74 | -$2.20 | -$42.09 | -$51.77 | -$2.85 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.2M | -$60.8M | -$106M | -$142M | -$124M | -$20.7M | -$38.4M |
| Capital expenditures | $339K | $235K | $26.0K | — | — | — | $200K |
| Free cash flow | -$20.5M | -$61.0M | -$106M | — | — | — | -$38.6M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $61.1M | $123M | $202M | $106M | $90.1M | $1.64M | $98.1M |
| Total assets | $139M | $371M | $287M | $277M | $191M | $6.16M | $122M |
| Total liabilities | $17.8M | $17.8M | $61.3M | $52.6M | $45.0M | $56.8M | $42.9M |
| Shareholders' equity | -$51.5M | $353M | $225M | $225M | -$45.0M | -$96.6M | $78.8M |
| Retained earnings | -$55.3M | -$125M | -$297M | -$466M | -$656M | -$117M | -$160M |
| Shares (wtd avg diluted) | 2.10M | 61.9M | 62.8M | 76.7M | 4.52M | 1.34M | 15.3M |
Every figure is extracted from Kalaris Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.